Intelligently
mining the market

-- ENA-001, with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease Designation for the treatment of Apnea of Prematurity by the FDA with eligibility for a priority review voucher -- -- The compound is also being developed for

-- ENA-001, a new chemical entity with a unique mechanism of action, is being developed as an agnostic respiratory stimulant for use in multiple patient populations experiencing acute respiratory depression -- -- Development is under way of intramuscular formulation for treatment of community drug

WOODCLIFF LAKE, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the Morgan Stanley 20 th Annual Global